NEW YORK (GenomeWeb News) – Fluidigm disclosed this week in a filing with the US Securities and Exchange Commission that Evan Jones and Patrick Jones have been elected by shareholders at a recent meeting to serve as Class I directors. They will serve on the board until the firm's 2014 annual meeting of stockholders.
Teri List-Stoll has been appointed to Danaher's board of directors. List-Stoll has served as SVP and treasurer of Procter & Gamble since 2009. Prior to joining P&G in 1994, she was affiliated with accounting firm Deloitte & Touche. Her term as a member of Danaher's board expires at the firm's 2012 annual meeting of shareholders.
Bruker this week said that William Knight has returned to the role of CFO of the firm and will continue to serve as interim COO while the firm searches for senior operational executives for the areas of manufacturing engineering, production, logistics, and global supply chain management.
Knight had taken over as interim CFO in June after Brian Monahan resigned from the position. He had previously served as CFO of the firm from 2004 until Feb. 1, 2010.
Former Solexa CEO John West has been named CEO of startup Personalis, a human genome analysis firm co-founded by West and Stanford University researchers Euan Ashley, Russ Altman, Atul Butte, and Mike Snyder.
Shimadzu UK has appointed Robert Keighley as its new spectroscopy and TOC business manager. Between 2000 and 2010 Keighley was employed by Varian and then Agilent, which acquired Varian last year, as product specialist for the Cary series of UV-Vis and NIR/FTIR products. From 1988 to 2000 he worked for Beckman Coulter in a number of roles including product manager for analytical centrifugation and product specialist for DNA sequencers, said Shimadzu.
Olink has named Simon Fredriksson as its new president and CEO. He has been promoted from EVP and chief scientific officer and takes over for Björn Ekström, who managed the company since its inception in 2004.
The firm also said that it has appointed new members to its board of directors, naming Bengt Ågerup as chairman. The other members of the board are are Olle Kämpe, Håkan Englund, Björn Ekström, Ulf Landegren, and Mats Nilsson.
Ågerup has held senior positions within Pharmacia and Biomatrix, and he started the company Q-Med, which was subsequently sold to Galderma in 2011. He also is the founder of Nxt2b, an investment firm that recently acquired a 49 percent stake in Olink.
Biomarker test startup Genomind said this week that it has hired Thomas Bartel as chief sales officer. He will lead the firm's efforts to further expand adoption of the Genecept Assay, a biomarker test designed to help inform treatment options for patients with mood disorders. Bartel was most recently VP of sales for Ipsogen and also had previously directed the national sales strategy of genomic and esoteric testing at Quest Diagnostics.
The David H. Murdock Research Institute announced this week that James Oblinger, a North Carolina State University professor in the Department of Food, Bioprocessing, and Nutrition Sciences, is the institute's new president.
Genetic test developer Population Diagnostics said this week that Walter Bodmer has joined its scientific advisory board. Bodmer, a human geneticist who has been knighted for his contributions to science, is currently head of the Cancer and Immunogenetics Laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.